Login to Your Account



Failed depression drug trial topples Cerecor shares

By Michael Fitzhugh
Staff Writer

Wednesday, November 30, 2016

Cerecor Inc. shares lost more than half their value Wednesday after the company reported that its fast-acting antidepressant candidate, CERC-301, failed to help patients with moderate to severe depression see significant improvement.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription